Genetic Disease

Advancing Genetic Disease Research with CRISPR From Mechanism to Precision Intervention
Advancing Genetic Disease Research with CRISPR From Mechanism to Precision Intervention

Advancing Genetic Disease Research with CRISPR

From Mechanism to Precision Intervention
CRISPR-Powered Genetic Disease Research

From Variant to Therapy: Decoding Genetic Diseases

Genetic diseases arise from diverse forms of genomic variation, including single-nucleotide variants (SNVs), insertions/deletions (indels), copy number variations, and repeat expansions. However, only a fraction of these variants exert functional effects that disrupt gene regulation, protein structure, or cellular pathways. Distinguishing causative mutations from background variation—and linking genotype to phenotype through mechanistic evidence—remains a central challenge in modern human genetics. 
With the rapid expansion of large-scale sequencing datasets and genome-wide association studies (GWAS), the bottleneck has shifted from variant discovery to functional interpretation and causal validation.
EDITGENE provides an integrated CRISPR-based platform that enables precise genome manipulation at endogenous loci, supporting a seamless transition from genetic insight to functional validation, disease modeling, and therapeutic strategy development.
Explore Cell Models Request Project Design
Variant Analysis

From Variant to Function: Identify Pathogenic Mutations

Genomic datasets often contain thousands of candidate variants per sample, yet only a subset contribute to disease phenotypes. Functional validation requires the ability to interrogate variants within their native chromatin and regulatory context, where epigenetic state, transcriptional regulation, and allele-specific effects can influence outcomes.

Leveraging CRISPR-mediated precision editing technologies (including base editing and prime editing), EDITGENE enables targeted introduction, correction, or modulation of variants at endogenous loci. This allows direct assessment of variant pathogenicity under controlled genetic backgrounds and supports rigorous genotype–phenotype mapping.

Key Applications:
· Functional validation of candidate variants
· Allele-specific effect analysis
· Dissection of genotype–phenotype relationships
Available Resources:
Pre-built mutation models covering key disease-associated genes:
CFTR · HTT · DMD · MECP2 · MYH7 · and more

Explore Point Mutation Models View Prime Editing Solutions
Disease Modeling

Build Genotype-Defined Systems

A fundamental requirement for mechanistic studies in genetic disease is the use of genetically defined and reproducible model systems. Heterogeneous genetic backgrounds can obscure causal relationships and introduce variability in phenotypic readouts.

CRISPR-based genome engineering enables the generation of isogenic model systems, where only the variant of interest differs between experimental conditions. This design is critical for isolating the functional contribution of specific mutations and improving experimental reproducibility.

In addition, combining genome editing with advanced biological systems—such as iPSC-derived cells and organoids—allows disease modeling across multiple layers of biological organization, from molecular pathways to tissue-level phenotypes.

What We Enable:
· Generation of isogenic cell models (WT vs mutant)
· Precise knock-in and knockout model development
· Scalable model construction across multiple systems
What We Enable:
Model Type Applications CRISPR Strategy
Immortalized cell lines Mechanistic studies, high-throughput screening Knockout, point mutation knock-in, CRISPR library screening
iPSC-derived cells Disease-relevant cell types Patient-derived iPSC editing, isogenic control generation
Organoids Tissue-level function, developmental processes Genome editing combined with organoid differentiation
Genetically engineered animals In vivo mechanism, efficacy evaluation Embryo editing, conditional knockout
Our Advantage:
By controlling genetic background and editing precision, researchers can establish direct causal links between genetic variation and phenotypic outcomes, significantly enhancing data interpretability.

Explore Disease Models Request Custom Model Development
Target Discovery & Therapeutic Development

From Mechanism to Intervention

Bridging the gap between genetic findings and therapeutic strategies requires systematic identification of disease-driving genes, modifier genes, and actionable intervention points. Functional genomics approaches are essential to move beyond correlation and establish therapeutic relevance.

CRISPR-based screening technologies—ranging from targeted perturbation to genome-wide knockout/activation libraries—enable unbiased discovery of genes that influence disease phenotypes. When combined with engineered disease models, these approaches support multi-layer validation of candidate targets.

Furthermore, precision editing technologies facilitate the evaluation of gene correction strategies, allele-specific interventions, and functional rescue experiments, providing critical insights into therapeutic feasibility.

Applications:
· Identification of functional targets and modifiers
· Validation of gene function through knockout or knock-in models
· Evaluation of therapeutic strategies in defined genetic contexts

CRISPR Strategies by Mutation Type

Model Type Recommended Strategy Technical Considerations
Loss-of-function (LoF) point mutations HDR-mediated precise correction Donor template design is critical to improve repair efficiency
Gain-of-function (GoF) mutations Allele-specific knockout sgRNA design must leverage sequence differences
Repeat expansions Selective disruption of mutant allele Target expanded regions or flanking sequences
Large deletions Gene replacement Insert functional copies into safe harbor loci
Ready-to-Use Tools:
· Target gene knockout and PE cell panels
· Gene correction and editing platforms
· Functional validation and screening workflows
Together, these tools enable a streamlined transition from candidate selection to functional validation and preclinical evaluation.
Browse Knockout (KO) Models Explore Point Mutation Models
Unified Research Workflow

A Unified Path from Variant to Therapeutic Strategy

From decoding genetic variation
· From understanding the origin of cancer (mutation)
· to uncovering cellular vulnerabilities (dependency)
· to identifying actionable targets (drug discovery)
EDITGENE enables a seamless research pipeline:

Variant → Function → Modeling → Target → Validation

This unified framework reduces experimental fragmentation and accelerates the generation of reproducible, translatable insights.

Platform Strength

Built for Precision and Speed

EDITGENE’s capabilities are supported by a robust technological foundation designed for accuracy, efficiency, and scalability:
· Advanced platforms: FLASH-KO™,  Prime Editing (Bingo™),  HES-KI
· Extensive mutation model library (CFTR, HTT, DMD, MECP2, MYH7,  etc.)
· Optimized editing strategies for diverse mutation types
· Monoclonal validation with sequencing confirmation (Sanger & NGS)
· 5–10 week turnaround for custom knockout models
· Global project support and delivery
From single-variant studies to large-scale functional genomics, EDITGENE delivers reliable solutions at every stage.

Contact Us

*
*
*
*
How did you hear about us：
Contact Us
*
*
*
*
How did you hear about us：
✖ service online